Retroperitoneal liposarcoma (RPL) presents a distinct "high-risk" disease spectrum, in which the phenotypic transition from well-differentiated liposarcoma (WDLPS) to dedifferentiated liposarcoma (DDLPS) constitutes a critical biological event leading to treatment failure and patient mortality. This review provides a systematic summary of the clinical features and multi-omics mechanisms underlying this transition. Clinically, this process is characterized by time-dependent malignant progression over approximately 7-8 years. Biologically, it reflects a layered evolutionary process involving a shared genomic trunk defined by MDM2 proto-oncogene (MDM2) and cyclin-dependent kinase 4 (CDK4), secondary driver events such as JUN proto-oncogene, AP-1 transcription factor subunit (JUN), and GLI family zinc finger 1 (GLI1), as well as progressive epigenetic locking. Recent single-cell multi-omics studies have further revealed that hypoxia and immunosuppressive pressure within the tumor microenvironment (TME) play pivotal roles in phenotypic plasticity through the selection of tumor adipocyte stem cells (tumor ASCs) with stem-like features. On the basis of this genome-epigenome-microenvironment coupling model, we discuss novel therapeutic strategies including induced redifferentiation, metabolic targeting, and microenvironment remodeling, thereby providing a theoretical foundation for interrupting the malignant progression of RPL.
Zhuang et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: